These trials involve finding solutions for patients who have more than one condition involving hematology, oncology, & bone and marrow transplant. Multispecialty studies focus on new ways to treat the whole patient through by studying the correlations between different diseases.
CHOP HAdV: Outcomes of Human Adenovirus (HAdV) Infection and Disease in Pediatric Allogeneic Stem Cell Transplant Recipients: A Prospective Multicenter Observational Cohort
Protocol ID: CHOP HAdV
Disease: Adenovirus
Who can participate?: Age less than 18 years of age at the time of transplant.
Lead Researcher: Monica I. Ardura
ISTH Database and DNA Biorespository for Congenital Antithrombin Deficiency- pilot/feasibility study
Protocol ID: ISTH Database Disease: 122 Who can participate?: Ages 0-21 years; AT deficiency confirmed Lead Researcher: Amy L. Dunn
Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer
Protocol ID: ALTE07C1 Disease: Multiple
Who can participate?: The patient must currently be enrolled or plan to be enrolled on a COG therapeutic study that aims to examine neuropsychological, social, emotional, and/or behavioral functioning. Lead Researcher: Mark A. Ranalli
Non-Invasive Diagnosis of Pediatric Pulmonary Invasive Mold Infections
Protocol ID: DOMINIC Who Can Participate?: Ages 3 months to 21 years Lead Researcher: Monica I. Ardura, DO, MSCS
Phase 1/1b Open Label Dose Escalation and Expansion study of Entrectinib (RXDX-101) in Children and Adolescents with recurrent or refractory solid tumors and primary CNS tumors, with or without TRK, ROS1, and ALK fusions
Protocol ID: RXDX-101
Disease: CNS/Solid Tumors
Who can participate?: Ages vary with patient cohorts- see protocol Lead Researcher: Mohamed Shebl AbdelBaki
Pilot Study in the Treatment of Refractory Adenovirus (ADV) Infection with related Donor ADV Cytotoxic T-Lymphocytes (ADV-CTLs)in Children, Adolescents and Young Adult Recipients
Protocol ID: NYMC 579-Adeno Disease: Cellular Therapy Who can participate?: Patients with Adenovirus infections post allogeneic HSCT or with primary immunodeficiencies with: Increasing ADV RT-PCR DNA (by 1 log) after 7 days or persistent quantitative ADV RT-PCR DNA copies after 14 days despite two weeks of appropriate anti-viral therapy and/or persistent clinical symptoms attributed to adenovirus, including pneumonitis, hemorrhagic cystitis, colitis, hepatitis AND/OR Medical intolerance to anti-viral therapies including: Lead Researcher: Rolla F. Abu-Arja
Pilot study of Adjunctive Natural Killer (NK) Cell Therapy to Treat Neonatal Disseminated Herpes Simplex Virus (HSV) Infection
Protocol ID: OSU CMV CTL Disease: Cellular Therapy Who can participate?: Infants < 6 months of age, Documented HSV infection by detection of HSV by PCR or culture from blood, superficial sites, or cerebrospinal fluid.Evidence of disseminated disease, defined as the presence of at least 2 non-contiguous sites of infection. Lead Researcher: Christopher P Ouellette
Testicular tissue cryopreservation for fertility preservation in male patients facing infertility-causing diseases or treatment regimens
Protocol ID: Testicular Cryo Who Can Participate?: Ages 0 to 99 Lead Researcher: Nicholas D. Yeager, MD
The Project: Every child Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
Protocol ID: APEC14B1 Disease: All Cancer Who can participate?: Subjects must be ≤ 25 years of age at time of original diagnosis, except for patients who are being screened specifically for eligibility onto a COG (or COG participating NCTN) therapeutic study, for whom there is a higher upper age limit. Lead Researcher: Mark A. Ranalli, MD
Umbrella Long-Term Follow-Up Protocol
Protocol ID: ALTE05N1
Disease: Multiple
Who can participate?: The patient must be enrolled on a frontline COG therapeutic trial for treatment of a primary malignancy and is nearing completion of or has recently completed protocol treatment (within the past 180 days)*; or the patient must have been enrolled on a COG (or Legacy Group) therapeutic or non-therapeutic trial targeted for long-term follow-up by ALTE05N1.
Lead Researcher: Mark A. Ranalli
Personalized Medicine: Pediatric Total Cancer Care Protocol
Protocol ID: MCC17319/TCC Sunshine Disease: Diagnosed or at Risk for Cancer Who can participate?: <18 years of age at diagnosis Lead Researcher: Bhuvana A. Setty, MD
A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children with SCID Disorders
Protocol ID: PIDTC 6901
Disease: SCID Disorders Who can participate?: < 2 years of age
Lead Researcher: Rolla F. Abu-Arja, MD
Ovarian Tissue Freezing For Fertility Preservation In Girls Facing A Fertility Threatening Medical Diagnosis or Treatment Regimen: A Study by the National Physicians Cooperative of the Oncofertility Consortium at Nationwide Children’s Hospital
Protocol ID: Ovarian Tissue Freezing for Fertility Preservation
Disease: All Cancer Who can participate?: Be female, less than or equal to 30 years old who are post-menarche.
Lead Researcher: Nicholas D. Yeager, MD
These trials involve finding solutions for patients who have more than one condition involving hematology, oncology, & bone and marrow transplant. Multispecialty studies focus on new ways to treat the whole patient through by studying the correlations between different diseases.
CHOP HAdV: Outcomes of Human Adenovirus (HAdV) Infection and Disease in Pediatric Allogeneic Stem Cell Transplant Recipients: A Prospective Multicenter Observational Cohort
Protocol ID: CHOP HAdV
Disease: Adenovirus
Who can participate?: Age less than 18 years of age at the time of transplant.
Lead Researcher: Monica I. Ardura
ISTH Database and DNA Biorespository for Congenital Antithrombin Deficiency- pilot/feasibility study
Protocol ID: ISTH Database Disease: 122 Who can participate?: Ages 0-21 years; AT deficiency confirmed Lead Researcher: Amy L. Dunn
Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer
Protocol ID: ALTE07C1 Disease: Multiple
Who can participate?: The patient must currently be enrolled or plan to be enrolled on a COG therapeutic study that aims to examine neuropsychological, social, emotional, and/or behavioral functioning. Lead Researcher: Mark A. Ranalli
Non-Invasive Diagnosis of Pediatric Pulmonary Invasive Mold Infections
Protocol ID: DOMINIC Who Can Participate?: Ages 3 months to 21 years Lead Researcher: Monica I. Ardura, DO, MSCS
Phase 1/1b Open Label Dose Escalation and Expansion study of Entrectinib (RXDX-101) in Children and Adolescents with recurrent or refractory solid tumors and primary CNS tumors, with or without TRK, ROS1, and ALK fusions
Protocol ID: RXDX-101
Disease: CNS/Solid Tumors
Who can participate?: Ages vary with patient cohorts- see protocol Lead Researcher: Mohamed Shebl AbdelBaki
Pilot Study in the Treatment of Refractory Adenovirus (ADV) Infection with related Donor ADV Cytotoxic T-Lymphocytes (ADV-CTLs)in Children, Adolescents and Young Adult Recipients
Protocol ID: NYMC 579-Adeno Disease: Cellular Therapy Who can participate?: Patients with Adenovirus infections post allogeneic HSCT or with primary immunodeficiencies with: Increasing ADV RT-PCR DNA (by 1 log) after 7 days or persistent quantitative ADV RT-PCR DNA copies after 14 days despite two weeks of appropriate anti-viral therapy and/or persistent clinical symptoms attributed to adenovirus, including pneumonitis, hemorrhagic cystitis, colitis, hepatitis AND/OR Medical intolerance to anti-viral therapies including: Lead Researcher: Rolla F. Abu-Arja
Pilot study of Adjunctive Natural Killer (NK) Cell Therapy to Treat Neonatal Disseminated Herpes Simplex Virus (HSV) Infection
Protocol ID: OSU CMV CTL Disease: Cellular Therapy Who can participate?: Infants < 6 months of age, Documented HSV infection by detection of HSV by PCR or culture from blood, superficial sites, or cerebrospinal fluid.Evidence of disseminated disease, defined as the presence of at least 2 non-contiguous sites of infection. Lead Researcher: Christopher P Ouellette
Testicular tissue cryopreservation for fertility preservation in male patients facing infertility-causing diseases or treatment regimens
Protocol ID: Testicular Cryo Who Can Participate?: Ages 0 to 99 Lead Researcher: Nicholas D. Yeager, MD
The Project: Every child Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
Protocol ID: APEC14B1 Disease: All Cancer Who can participate?: Subjects must be ≤ 25 years of age at time of original diagnosis, except for patients who are being screened specifically for eligibility onto a COG (or COG participating NCTN) therapeutic study, for whom there is a higher upper age limit. Lead Researcher: Mark A. Ranalli, MD
Umbrella Long-Term Follow-Up Protocol
Protocol ID: ALTE05N1
Disease: Multiple
Who can participate?: The patient must be enrolled on a frontline COG therapeutic trial for treatment of a primary malignancy and is nearing completion of or has recently completed protocol treatment (within the past 180 days)*; or the patient must have been enrolled on a COG (or Legacy Group) therapeutic or non-therapeutic trial targeted for long-term follow-up by ALTE05N1.
Lead Researcher: Mark A. Ranalli
Personalized Medicine: Pediatric Total Cancer Care Protocol
Protocol ID: MCC17319/TCC Sunshine Disease: Diagnosed or at Risk for Cancer Who can participate?: <18 years of age at diagnosis Lead Researcher: Bhuvana A. Setty, MD
A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children with SCID Disorders
Protocol ID: PIDTC 6901
Disease: SCID Disorders Who can participate?: < 2 years of age
Lead Researcher: Rolla F. Abu-Arja, MD
Ovarian Tissue Freezing For Fertility Preservation In Girls Facing A Fertility Threatening Medical Diagnosis or Treatment Regimen: A Study by the National Physicians Cooperative of the Oncofertility Consortium at Nationwide Children’s Hospital
Protocol ID: Ovarian Tissue Freezing for Fertility Preservation
Disease: All Cancer Who can participate?: Be female, less than or equal to 30 years old who are post-menarche.
Lead Researcher: Nicholas D. Yeager, MD
CHOP HAdV: Outcomes of Human Adenovirus (HAdV) Infection and Disease in Pediatric Allogeneic Stem Cell Transplant Recipients: A Prospective Multicenter Observational Cohort
Protocol ID: CHOP HAdV
Disease: Adenovirus
Who can participate?: Age less than 18 years of age at the time of transplant.
Lead Researcher: Monica I. Ardura
ISTH Database and DNA Biorespository for Congenital Antithrombin Deficiency- pilot/feasibility study
Protocol ID: ISTH Database Disease: 122 Who can participate?: Ages 0-21 years; AT deficiency confirmed Lead Researcher: Amy L. Dunn
Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer
Protocol ID: ALTE07C1 Disease: Multiple
Who can participate?: The patient must currently be enrolled or plan to be enrolled on a COG therapeutic study that aims to examine neuropsychological, social, emotional, and/or behavioral functioning. Lead Researcher: Mark A. Ranalli
Non-Invasive Diagnosis of Pediatric Pulmonary Invasive Mold Infections
Protocol ID: DOMINIC Who Can Participate?: Ages 3 months to 21 years Lead Researcher: Monica I. Ardura, DO, MSCS
Phase 1/1b Open Label Dose Escalation and Expansion study of Entrectinib (RXDX-101) in Children and Adolescents with recurrent or refractory solid tumors and primary CNS tumors, with or without TRK, ROS1, and ALK fusions
Protocol ID: RXDX-101
Disease: CNS/Solid Tumors
Who can participate?: Ages vary with patient cohorts- see protocol Lead Researcher: Mohamed Shebl AbdelBaki
Pilot Study in the Treatment of Refractory Adenovirus (ADV) Infection with related Donor ADV Cytotoxic T-Lymphocytes (ADV-CTLs)in Children, Adolescents and Young Adult Recipients
Protocol ID: NYMC 579-Adeno Disease: Cellular Therapy Who can participate?: Patients with Adenovirus infections post allogeneic HSCT or with primary immunodeficiencies with: Increasing ADV RT-PCR DNA (by 1 log) after 7 days or persistent quantitative ADV RT-PCR DNA copies after 14 days despite two weeks of appropriate anti-viral therapy and/or persistent clinical symptoms attributed to adenovirus, including pneumonitis, hemorrhagic cystitis, colitis, hepatitis AND/OR Medical intolerance to anti-viral therapies including: Lead Researcher: Rolla F. Abu-Arja
Pilot study of Adjunctive Natural Killer (NK) Cell Therapy to Treat Neonatal Disseminated Herpes Simplex Virus (HSV) Infection
Protocol ID: OSU CMV CTL Disease: Cellular Therapy Who can participate?: Infants < 6 months of age, Documented HSV infection by detection of HSV by PCR or culture from blood, superficial sites, or cerebrospinal fluid.Evidence of disseminated disease, defined as the presence of at least 2 non-contiguous sites of infection. Lead Researcher: Christopher P Ouellette
Testicular tissue cryopreservation for fertility preservation in male patients facing infertility-causing diseases or treatment regimens
Protocol ID: Testicular Cryo Who Can Participate?: Ages 0 to 99 Lead Researcher: Nicholas D. Yeager, MD
The Project: Every child Protocol: A Registry, Eligibility Screening, Biology and Outcome Study
Protocol ID: APEC14B1 Disease: All Cancer Who can participate?: Subjects must be ≤ 25 years of age at time of original diagnosis, except for patients who are being screened specifically for eligibility onto a COG (or COG participating NCTN) therapeutic study, for whom there is a higher upper age limit. Lead Researcher: Mark A. Ranalli, MD
Umbrella Long-Term Follow-Up Protocol
Protocol ID: ALTE05N1
Disease: Multiple
Who can participate?: The patient must be enrolled on a frontline COG therapeutic trial for treatment of a primary malignancy and is nearing completion of or has recently completed protocol treatment (within the past 180 days)*; or the patient must have been enrolled on a COG (or Legacy Group) therapeutic or non-therapeutic trial targeted for long-term follow-up by ALTE05N1.
Lead Researcher: Mark A. Ranalli
Personalized Medicine: Pediatric Total Cancer Care Protocol
Protocol ID: MCC17319/TCC Sunshine Disease: Diagnosed or at Risk for Cancer Who can participate?: <18 years of age at diagnosis Lead Researcher: Bhuvana A. Setty, MD
A Prospective Natural History Study of Diagnosis, Treatment and Outcomes of Children with SCID Disorders
Protocol ID: PIDTC 6901
Disease: SCID Disorders Who can participate?: < 2 years of age
Lead Researcher: Rolla F. Abu-Arja, MD
Ovarian Tissue Freezing For Fertility Preservation In Girls Facing A Fertility Threatening Medical Diagnosis or Treatment Regimen: A Study by the National Physicians Cooperative of the Oncofertility Consortium at Nationwide Children’s Hospital
Protocol ID: Ovarian Tissue Freezing for Fertility Preservation
Disease: All Cancer Who can participate?: Be female, less than or equal to 30 years old who are post-menarche.
Lead Researcher: Nicholas D. Yeager, MD
Protocol ID: CHOP HAdV
Disease: Adenovirus
Who can participate?: Age less than 18 years of age at the time of transplant.
Lead Researcher: Monica I. Ardura
Protocol ID: CHOP HAdV
Disease: Adenovirus
Who can participate?: Age less than 18 years of age at the time of transplant.
Lead Researcher: Monica I. Ardura
Protocol ID: ISTH Database Disease: 122 Who can participate?: Ages 0-21 years; AT deficiency confirmed Lead Researcher: Amy L. Dunn
Protocol ID: ISTH Database
Disease: 122
Who can participate?: Ages 0-21 years; AT deficiency confirmed
Lead Researcher: Amy L. Dunn
Protocol ID: ALTE07C1 Disease: Multiple
Who can participate?: The patient must currently be enrolled or plan to be enrolled on a COG therapeutic study that aims to examine neuropsychological, social, emotional, and/or behavioral functioning. Lead Researcher: Mark A. Ranalli
Protocol ID: ALTE07C1
Disease: Multiple
Who can participate?: The patient must currently be enrolled or plan to be enrolled on a COG therapeutic study that aims to examine neuropsychological, social, emotional, and/or behavioral functioning.
Lead Researcher: Mark A. Ranalli
Protocol ID: DOMINIC Who Can Participate?: Ages 3 months to 21 years Lead Researcher: Monica I. Ardura, DO, MSCS
Protocol ID: DOMINIC
Who Can Participate?: Ages 3 months to 21 years
Lead Researcher: Monica I. Ardura, DO, MSCS
Protocol ID: RXDX-101
Disease: CNS/Solid Tumors
Who can participate?: Ages vary with patient cohorts- see protocol Lead Researcher: Mohamed Shebl AbdelBaki
Protocol ID: RXDX-101
Disease: CNS/Solid Tumors
Who can participate?: Ages vary with patient cohorts- see protocol
Lead Researcher: Mohamed Shebl AbdelBaki
Protocol ID: NYMC 579-Adeno Disease: Cellular Therapy Who can participate?: Patients with Adenovirus infections post allogeneic HSCT or with primary immunodeficiencies with: Increasing ADV RT-PCR DNA (by 1 log) after 7 days or persistent quantitative ADV RT-PCR DNA copies after 14 days despite two weeks of appropriate anti-viral therapy and/or persistent clinical symptoms attributed to adenovirus, including pneumonitis, hemorrhagic cystitis, colitis, hepatitis AND/OR Medical intolerance to anti-viral therapies including: Lead Researcher: Rolla F. Abu-Arja
Protocol ID: NYMC 579-Adeno
Disease: Cellular Therapy
Who can participate?: Patients with Adenovirus infections post allogeneic HSCT or with primary immunodeficiencies with: Increasing ADV RT-PCR DNA (by 1 log) after 7 days or persistent quantitative ADV RT-PCR DNA copies after 14 days despite two weeks of appropriate anti-viral therapy and/or persistent clinical symptoms attributed to adenovirus, including pneumonitis, hemorrhagic cystitis, colitis, hepatitis AND/OR Medical intolerance to anti-viral therapies including:
Lead Researcher: Rolla F. Abu-Arja
Protocol ID: OSU CMV CTL Disease: Cellular Therapy Who can participate?: Infants < 6 months of age, Documented HSV infection by detection of HSV by PCR or culture from blood, superficial sites, or cerebrospinal fluid.Evidence of disseminated disease, defined as the presence of at least 2 non-contiguous sites of infection. Lead Researcher: Christopher P Ouellette
Protocol ID: OSU CMV CTL
Who can participate?: Infants < 6 months of age, Documented HSV infection by detection of HSV by PCR or culture from blood, superficial sites, or cerebrospinal fluid.Evidence of disseminated disease, defined as the presence of at least 2 non-contiguous sites of infection.
Lead Researcher: Christopher P Ouellette
Protocol ID: Testicular Cryo Who Can Participate?: Ages 0 to 99 Lead Researcher: Nicholas D. Yeager, MD
Protocol ID: Testicular Cryo
Who Can Participate?: Ages 0 to 99
Lead Researcher: Nicholas D. Yeager, MD
Protocol ID: APEC14B1 Disease: All Cancer Who can participate?: Subjects must be ≤ 25 years of age at time of original diagnosis, except for patients who are being screened specifically for eligibility onto a COG (or COG participating NCTN) therapeutic study, for whom there is a higher upper age limit. Lead Researcher: Mark A. Ranalli, MD
Protocol ID: APEC14B1
Disease: All Cancer
Who can participate?: Subjects must be ≤ 25 years of age at time of original diagnosis, except for patients who are being screened specifically for eligibility onto a COG (or COG participating NCTN) therapeutic study, for whom there is a higher upper age limit.
Lead Researcher: Mark A. Ranalli, MD
Protocol ID: ALTE05N1
Disease: Multiple
Who can participate?: The patient must be enrolled on a frontline COG therapeutic trial for treatment of a primary malignancy and is nearing completion of or has recently completed protocol treatment (within the past 180 days)*; or the patient must have been enrolled on a COG (or Legacy Group) therapeutic or non-therapeutic trial targeted for long-term follow-up by ALTE05N1.
Lead Researcher: Mark A. Ranalli
Protocol ID: ALTE05N1
Disease: Multiple
Who can participate?: The patient must be enrolled on a frontline COG therapeutic trial for treatment of a primary malignancy and is nearing completion of or has recently completed protocol treatment (within the past 180 days)*; or the patient must have been enrolled on a COG (or Legacy Group) therapeutic or non-therapeutic trial targeted for long-term follow-up by ALTE05N1.
Lead Researcher: Mark A. Ranalli
Protocol ID: MCC17319/TCC Sunshine Disease: Diagnosed or at Risk for Cancer Who can participate?: <18 years of age at diagnosis Lead Researcher: Bhuvana A. Setty, MD
Protocol ID: MCC17319/TCC Sunshine
Disease: Diagnosed or at Risk for Cancer
Who can participate?: <18 years of age at diagnosis
Lead Researcher: Bhuvana A. Setty, MD
Protocol ID: PIDTC 6901
Disease: SCID Disorders Who can participate?: < 2 years of age
Lead Researcher: Rolla F. Abu-Arja, MD
Protocol ID: PIDTC 6901
Disease: SCID Disorders
Who can participate?: < 2 years of age
Lead Researcher: Rolla F. Abu-Arja, MD
Protocol ID: Ovarian Tissue Freezing for Fertility Preservation
Disease: All Cancer Who can participate?: Be female, less than or equal to 30 years old who are post-menarche.
Lead Researcher: Nicholas D. Yeager, MD
Protocol ID: Ovarian Tissue Freezing for Fertility Preservation
Who can participate?: Be female, less than or equal to 30 years old who are post-menarche.
Lead Researcher: Nicholas D. Yeager, MD
